Multiple gene aberrations and breast cancer: lessons from super-responders
- 2.5k Downloads
The presence of multiple molecular aberrations in patients with breast cancer may correlate with worse outcomes.
We performed in-depth molecular analysis of patients with estrogen receptor-positive, HER2-negative, hormone therapy-refractory breast cancer, who achieved partial or complete responses when treated with anastrozole and everolimus. Tumors were analyzed using a targeted next generation sequencing (NGS) assay in a Clinical Laboratory Improvement Amendments laboratory. Genomic libraries were captured for 3,230 exons in 182 cancer-related genes plus 37 introns from 14 genes often rearranged in cancer and sequenced to high coverage. Patients received anastrozole (1 mg PO daily) and everolimus (5 or 10 mg PO daily). Thirty-two patients with breast cancer were treated on study and 5 (16 %) achieved a partial or complete response. Primary breast tissue was available for NGS testing in three of the responders (partial response with progression free survival of 11 and 14 months, respectively; complete response with progression free survival of 9+ months). The following molecular aberrations were observed: PTEN loss by immunohistochemistry, CCDN1 and FGFR1 amplifications, and PRKDC re-arrangement (NGS) (patient #1); PIK3CA and PIK3R1 mutations, and CCDN1, FGFR1, MYC amplifications (patient #2); TP53 mutation, CCNE1, IRS2 and MCL1 amplifications (patient #3). Some (but not all) of these aberrations converge on the PI3K/AKT/mTOR pathway, perhaps accounting for response.
Patients with estrogen receptor-positive breast cancer can achieve significant responses on a combination of anastrozole and everolimus, even in the presence of multiple molecular aberrations. Further study of next generation sequencing-profiled tumors for convergence and resistance pathways is warranted.
KeywordsBreast cancer Genomic aberrations Next generation sequencing
Gene aberrations including, but not limited to, mutations, amplifications and rearrangements drive tumor growth. Aberrations are common in breast cancer in genes such as HER2 (ERBB2), BRCA, PIK3CA, TP53, GATA3, PTEN and others [1, 2, 3, 4, 5, 6]. The presence of multiple gene abnormalities may also serve as an indicator of genetic instability and therefore of poor patient prognosis [7, 8].
Hormone therapy is the treatment of choice for estrogen (ER) and progesterone (PR)-positive breast cancer, but acquired resistance is a significant challenge. The PI3K/AKT/mTOR pathway becomes activated and utilized by cancer cells to bypass the effects of endocrine therapy [9, 10, 11]. While investigating the combination of anastrozole (an aromatase inhibitor that blocks estrogen production) and everolimus (an mTOR inhibitor), we noted partial or complete responses (PR or CR) with progression-free survival (PFS) of at least 9 months in five patients with breast cancer of 32 treated . We performed next-generation sequencing (NGS) on three of the responders with available tissue. In depth analysis revealed that, despite their responses, their tumors demonstrated multiple aberrations in genes including CCND1, CCNE1, FGFR1, MYC, IRS2, MCL1, PIK3CA, PIK3R1, PRKDC, and TP53. The implications of these diverse aberrations for understanding response and resistance are discussed.
Clinical Characteristics and Responses of Super-Responders Treated with Anastrozole and Everolimus
Age at Treatment (years)
Date of Diagnosis
Date of Biopsy
90 % Positive
95 % Positive
95 % Positive
60 % Positive
80 % Positive
Prior Treatment in Metastatic Setting
Paclitaxel (3 months) 5-fluorouracil, doxorubicin, cyclophosphamide (1 month) Tamoxifen (3 months) Capacitabine ( 3 months)
Tamoxifen (2 months) Paclitaxel, bevacizumaba Vinorelbinea Fulvestrant (3 months) Ixabepilonea Docetaxel (9 months) Docetaxel, doxorubicin, cyclophosphamide (3 months)
Tamoxifen, zoledronic acid (6 months) Letrozole (4 months)
Prior Treatment with Aromatase Inhibitor in Metastatic Setting (Duration)
Yes (4 months)
Molecular alterations (Please reference Additional file 1: Table S1)
Progression Free Survival (months)
Best Response (%)
Patient #1 is a 38-year old woman with ER-positive (90 %), PR-positive (60 %), HER2-negative, invasive ductal carcinoma diagnosed in August 2009. The patient was referred to the Clinical Center for Targeted Therapy at MD Anderson Cancer Center in February 2011. Previous therapies in the metastatic setting included: (1) paclitaxel; (2) 5-fluorouracil, doxorubicin, cyclophosphamide; (3) tamoxifen; and (4) capecitabine. Immunohistochemistry revealed complete nuclear PTEN loss. NGS of left breast tumor tissue dated August 2009 revealed amplifications in CCDN1 and FGFR1 in addition to a rearrangement in PRKDC.
Patient #2 is a 48-year old woman with ER-positive (95 %), PR-positive (80 %), HER2- negative, invasive ductal carcinoma diagnosed in September 2007. At that time, metastatic disease was found in the pleura and bones. The patient was referred to our clinic in March 2011. Previous therapies in the metastatic setting included: (1) tamoxifen; (2) paclitaxel with bevacizumab; (3) vinorelbine; (4) fulvestrant; (5) ixabepilone; (6) docetaxel; and (7) docetaxel, doxorubicin and cyclophosphamide. Immunohistochemistry showed PTEN to be present. NGS of malignant tissue from the left breast dated September 2007 revealed mutations in PIK3CA and PIK3R1 in addition to amplifications in CCDN1, FGFR1 and MYC.
The patient was treated with anastrozole 1 mg PO daily and everolimus 5 mg PO daily starting March 2011. She achieved a PR (38 % decrease in measureable disease). After 14 months on study, she showed signs of progression. At that time, a third agent, fulvestrant (an estrogen receptor antagonist) was added as per protocol for triple combination therapy. Five months later, she continues on this triple-agent treatment.
Patient #3 is a 44-year old woman with ER-positive (>95 %), PR-negative, HER2-negative, invasive ductal carcinoma diagnosed in September 2010. The patient was referred to our clinic in October 2011. Previous therapies in the metastatic setting included: (1) tamoxifen with zoledronic acid and (2) letrozole (progression free survival = 4 months). Immunohistochemistry showed intact PTEN. NGS of tissue from the primary left breast tumor at the time of diagnosis revealed a mutation in TP53 and amplifications in CCNE1, IRS2 and MCL1.
We present an in-depth analysis of three patients with advanced, refractory breast cancer who attained remarkable responses despite the fact that their tumors harbored multiple gene alterations (Additional file 1: Table S1). Of interest, in each case, despite the complexity of aberrations revealed by NGS, many of the molecular abnormalities can be shown to converge, at least in part, on the PI3K/AKT/mTOR axis, perhaps accounting for the responses. On the other hand, some of the genes involved also modulate other pathways, and this fact may explain why two of the patients attained only partial responses, and eventually relapsed.
In patient #1, who had ER/PR-positive disease, abnormalities included: PTEN loss; CCDN1 and FGFR1 amplifications and a re-arrangement in PRKDC. Yet, she achieved a durable PR on anastrozole and everolimus. PTEN loss is known to activate the PI3K pathway , which might easily explain the response to the mTOR inhibitor everolimus. Of interest, however, the other aberrant genes detected in this patient’s tumor might also affect this pathway. For instance, CCND1, also known as BCL1, is down regulated by mTOR inhibition [14, 15]. FGFR1 encodes a tyrosine kinase receptor belonging to fibroblast growth factor receptor (FGFR) family; this gene is amplified in 9 to 15 % of breast cancers [16, 17, 18]. Activation of FGFR induces PI3K and AKT pathway activity through recruitment and tyrosine phosphorylation of the docking protein Gab . Finally, PRKDC was rearranged in patient #1. This gene is a member of the PI3K family and encodes the catalytic subunit of the DNA-dependent protein kinase (DNA-PK). It functions with the Ku70/Ku80 heterodimer protein in DNA double strand break repair and recombination . Overall, though there were several different aberrations in this patient, each has some impact on PI3K/AKT/mTOR signaling. Yet, some of the aberrations (e.g., FGFR1) also activate other signaling pathways such as MAP kinase , which might explain why complete response was not attained and/or the eventual progression that developed after 11 months.
In patient #2, who also achieved a durable PR (14 months) on anastrozole and everolimus, multiple aberrations were seen as well. NGS of malignant tissue revealed mutations in PIK3CA and PIK3R1, in addition to amplifications in CCDN1, FGFR1 and MYC. Responses of patients with PIK3CA-mutant breast, gynecologic and other tumors to mTOR inhibitors has been previously reported [3, 22, 23, 24, 25, 26]. The crosstalk between CCND1 and FGFR1 (both amplified in this patient) and the PI3K/AKT/mTOR pathway has been discussed above. MYC encodes a transcription factor with multiple functions, including interaction with the PI3K/AKT/mTOR axis as evidenced by the observation that MYC-induced proliferation and transformation require AKT-mediated phosphorylation of FoxO proteins . Of interest, both this patient and patient #1 harbored FGFR1 aberrations and, as mentioned, FGFR1 can activate both PI3K and MAPK signals, hence potentially explaining both initial response to everolimus (via PI3K activation) and eventual resistance (via MAPK). MYC might also play a role in limiting the response of this patient to less than a CR, since MYC regulates expression of a broad array of genes via its functions as a transcription factor, transcriptional repressor, and regulator of global chromatin structure by means of recruitment of histone acetyltransferases .
Patient #3, who attained a CR on therapy, demonstrated a mutation in TP53 and amplifications in CCNE1, IRS2 and MCL1. TP53 is a regulator of PTEN, which is in itself a negative regulatory of PIK3CA . CCNE1 degradation is regulated by GSK-3β, which is directly phosphorylated by AKT [31, 32]. Insulin receptor substrates (IRS) serve as downstream messengers from activated cell surface receptors to numerous signaling pathway cascades including PI3K . Finally, mTORC1 promotes survival in part through translational control of MCL-1 . Previous studies have demonstrated up-regulation of the PI3K/AKT/mTOR pathway as a mechanism of resistance to hormone therapy [35, 36, 37, 38, 39, 40], and clinical trials combining hormone therapy with mTOR inhibitors have shown promise in breast and endometrial cancers [41, 42, 43]. Further, the combination of exemestane (an aromatase inhibitor) and everolimus was FDA approved for metastatic breast cancer. Other possibilities for the response in this patient may be the effect of anastrazole or the development of new molecular alterations since the primary diagnosis as molecular profiling was done on primary breast tissue.
In our study of anastrozole and everolimus in hormone receptor-positive breast cancers we observed salutary activity in patients with multiple gene aberrations. Patient #1 and Patient #2 demonstrated direct alterations in the PI3K/AKT/mTOR pathway (PTEN loss and PIK3CA mutation, respectively) in addition to multiple gene amplifications and additional rearrangements or mutations. It is therefore plausible that these patients responded because their tumors maintained dependence on or addiction to the PI3K/AKT/mTOR axis despite the presence of additional gene alterations. Recently, Hortobagyi et al.  reported that patients treated on the Phase 2 BOLERO-2 study had a greater treatment effect if they had no or only 1 genetic alteration in PI3K or FGFR pathways or CCND1. Some of the additional molecular alterations demonstrated by NGS in our patients may however also modulate the PI3K/AKT/mTOR axis, as noted above, explaining our findings. Systems biology approaches that map convergence pathways may therefore enhance treatment for patients [5, 6, 44, 45]. Alternatively, an eventual relapse (and in patients #1 and #2, partial, rather than complete, response) could be the result of the actions of the additional molecular alterations. Of interest, at the time of progression, fulvestrant, an estrogen receptor antagonist, was added to anastrozole and everolimus in patient #2, with a 5+ month disease stabilization. This strategy (adding an agent rather than changing regimens) is consistent with observations in patients with HER2-positive metastatic breast cancer that continuation of trastuzumab beyond progression can be beneficial  as well as our observations on resistance and retreatment . The mechanism is unclear but could relate to residual sensitive tumor cells that co-exist with the emerging resistant clone.
As part of a dose escalation study of the aromatase inhibitor anastrozole and the mTOR inhibitor everolimus (NCT01197170), we performed NGS on patients who had attained PR or CR (and had a PFS of at least nine months) and available tissue. NGS testing was not a part of standard care, but was done retrospectively after responses were seen. Research involving human subjects (including human material or human data) that is reported in this study was conducted in accordance with the guidelines of the MD Anderson Internal Review Board, and patients signed informed consent for all experimental therapeutic interventions and for the deposit of NGS results.
Evaluation of HER2/neu amplification, estrogen and progesterone receptor status
Under CLIA conditions, immunohistochemistry was used to measure of HER2/neu, estrogen and progesterone receptors. Estrogen and progesterone receptors were assessed using antibody 6 F11 (Novocastra Laboratories, Ltd., Newcastle Upon Tyne, UK). Alternatively, fluorescence in situ hybridization (FISH) was used to measure the copy number of HER2/neu.
Molecular analysis using NGS was performed on archival formalin-fixed, paraffin-embedded tissue. Genomic libraries were captured for 3230 exons in 182 cancer-related genes plus 37 introns from 14 genes often rearranged in cancer and sequenced to average median depth of 734× with 99 % of bases covered >100× (Foundation Medicine, Cambridge, MA, USA).
Evaluation of PTEN expression
Evaluation of response
Responses were assessed after three cycles (about 12 weeks) or earlier at the discretion of the treating physician. All radiological tests were assessed by an MD Anderson radiologist. In addition, results were reviewed in a departmental tumor measurement clinic and by the attending physician. RECIST criteria were used for progressive disease (PD), stable disease (SD), partial and complete responses (PR and CR).
In each of these “super-responders,” tumor tissue that was derived from diagnosis was analyzed by NGS. It is conceivable that the number of aberrations increased by the time the patient was treated in our clinic, which was between one and 3.5 years after diagnosis, especially since each of these patients had received multiple intervening therapies, and now had advanced metastatic disease. Despite these limitations, NGS on tissue from diagnosis was informative, and revealed abnormalities that were actionable, similar to an earlier report by Kalinsky et al. . Optimizing future studies probably requires fresh biopsies at the time of each relapse. However, in their absence, tumor tissue derived from an earlier point in time still yields useful information. Our observations suggest that NGS can help unravel the mechanisms of response and resistance, and warrants additional investigation as a clinical tool to optimize treatment.
Ethical approval of this study was obtained from the MD Anderson Internal Review Board. Each patient willingly provided written informed consent for all treatment related activities, including the publication of individual outcomes, accompanying images and the deposit of NGS data into an institutional database.
This work was supported in part by a grant from Foundation Medicine.
- 9.Jegg AM, Ward TM, Iorns E, Hoe N, Zhou J, Liu X, Singh S, Landgraf R, Pegram MD: PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells. Breast Cancer Res Treat 2012.Google Scholar
- 10.Nicholson RI, Hutcheson IR, Hiscox SE, Knowlden JM, Giles M, Barrow D, et al. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr Relat Cancer. 2005;12 Suppl 1:S29–36.CrossRefPubMedGoogle Scholar
- 12.Wheler J, Moulder S, Naing A, Janku F, Piha-Paul SA, Falchook G, Zinner R, Tsimberidou AM, Fu S, Hong DS et al.: A dose-escalation study of anastrozole and everolimus in patients with advanced gynecologic and brest malignancies: tolerance, biological activity, and moleculer alterations in the PI3K/AKT/mTOR pathway. Cancer Res 2013, 73(8): Abstract 3514.Google Scholar
- 24.Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, et al. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res. 2012;18(20):5796–805.CrossRefPubMedGoogle Scholar
- 25.Hortobagyi GN, Piccart-Gebhart MJ, Rugo HS, Burris HA, Campone M, Noguchi S, Perez A, Deleu I, Shtivelband M, Provencher L et al.: Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2. J Clin Oncol 2013; 31(18_suppl): LBA509.Google Scholar
- 42.Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27(16):2630–7.CrossRefPubMedGoogle Scholar
- 43.Slomovitz BM, Brown J, Johnston TA, Mura D, Levenback C, Wolf J, Adler KR, Lu H, Coleman RL: A phase II study or everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 2011; 29(suppl; abstr 5012).Google Scholar
- 46.Petrelli F, Barni S. A Pooled Analysis of 2618 Patients Treated with Trastuzumab Beyond Progression for Advanced Breast Cancer, Clin Breast Cancer. 2012.Google Scholar
- 50.Janku F, Broaddus R, Bakker R, Hong D, Stepanek V, Naing A, Falchook G, Fu S, Wheler JJ, Piha-Paul SA et al.: PTEN assessment and PI3K/mTOR inhibitors: Importance of simultaneous assessment of MAPK pathway aberrations. J Clin Oncol 2012; 30:suppl; abstr 10510.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.